Renal Unit, Joslin Diabetes Center, Boston, MA 02215, USA.
Clin J Am Soc Nephrol. 2010 Sep;5(9):1595-601. doi: 10.2215/CJN.09301209. Epub 2010 Jul 29.
The benefits and risks of aggressive glycemic control in diabetes mellitus complicated by end-stage kidney failure remain uncertain but have importance because of the large patient population with inferior overall prognosis. Recent large observational studies with differing methodologies reached somewhat contrasting conclusions regarding the association of hemoglobin A1c with survival in diabetic chronic hemodialysis patients.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study supplements the authors' previous analysis (which found no correlation) by extending the follow-up period to 3 years and using time-dependent survival models with repeated measures. Among 24,875 nationally distributed study patients, 94.5% had type 2 diabetes, allowing additional analysis in the subset with type 1 diabetes. Data were collected at baseline and every quarter to a maximum of 3 years' follow-up.
Adjusted standard and time-dependent Cox models indicated that only extremes of glycemia were associated with inferior survival. There was no effect modification by serum albumin levels, a marker of protein nutrition status, and no trend associated with random glucose measurements in a post hoc analysis. In type 1 diabetic patients, upper extreme hemoglobin A1c values indicated lower survival risk.
Sustained extremes of glycemia were only variably and weakly associated with decreased survival in this population. In the absence of randomized, controlled trials, these results suggest that aggressive glycemic control cannot be routinely recommended for all diabetic hemodialysis patients on the basis of reducing mortality risk. Physicians are encouraged to individualize glycemic targets based on potential risks and benefits in diabetic ESRD patients.
在并发终末期肾衰竭的糖尿病患者中,积极控制血糖的益处和风险仍不确定,但由于预后较差的患者群体庞大,因此具有重要意义。最近的一些大型观察性研究采用不同的方法学得出了关于血红蛋白 A1c 与糖尿病慢性血液透析患者生存之间关联的结论略有不同。
设计、环境、参与者和测量方法:本研究通过将随访期延长至 3 年,并使用具有重复测量的时间依赖性生存模型,对作者之前的分析(未发现相关性)进行了补充。在 24875 名全国分布的研究患者中,94.5%患有 2 型糖尿病,允许对 1 型糖尿病亚组进行额外分析。数据在基线和每季度收集,最多可随访 3 年。
调整后的标准和时间依赖性 Cox 模型表明,只有血糖的极端值与较差的生存相关。在亚组分析中,血清白蛋白水平(蛋白质营养状况的标志物)没有影响修饰作用,随机血糖测量也没有趋势与生存风险相关。在 1 型糖尿病患者中,血红蛋白 A1c 值的上限表示较低的生存风险。
在该人群中,仅血糖持续极端与生存降低存在可变性和弱关联。在缺乏随机对照试验的情况下,这些结果表明,不能基于降低死亡率风险,常规推荐所有糖尿病血液透析患者进行积极的血糖控制。鼓励医生根据糖尿病 ESRD 患者的潜在风险和获益来个体化血糖目标。